1530 Stock Overview
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.05 |
| 52 Week High | HK$8.10 |
| 52 Week Low | HK$4.91 |
| Beta | 0.78 |
| 1 Month Change | 2.20% |
| 3 Month Change | 2.37% |
| 1 Year Change | -22.44% |
| 3 Year Change | -18.68% |
| 5 Year Change | -58.28% |
| Change since IPO | -35.29% |
Recent News & Updates
Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16
Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now
Jan 26Recent updates
Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now
Jan 26These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely
Dec 30Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Dec 11Is 3SBio (HKG:1530) A Risky Investment?
Sep 12Calculating The Fair Value Of 3SBio Inc. (HKG:1530)
Aug 07With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case
Jul 193SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
Apr 13Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Feb 27Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?
Jan 17Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?
Nov 24We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Oct 213SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate
Oct 04Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?
Apr 21We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Mar 31We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Dec 09An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued
Nov 21We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 103SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate
Aug 223SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?
Mar 11Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 18
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued
Jan 31A Look At 3SBio's (HKG:1530) Share Price Returns
Jan 03Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?
Dec 16What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?
Dec 01Shareholder Returns
| 1530 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 6.9% | 5.7% | 3.6% |
| 1Y | -22.4% | -40.7% | -10.1% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned -40.7% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned -10.1% over the past year.
Price Volatility
| 1530 volatility | |
|---|---|
| 1530 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1530 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1530's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,411 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation.
3SBio Inc. Fundamentals Summary
| 1530 fundamental statistics | |
|---|---|
| Market cap | HK$14.41b |
| Earnings (TTM) | HK$1.67b |
| Revenue (TTM) | HK$8.44b |
8.6x
P/E Ratio1.7x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1530 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.82b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥6.64b |
| Other Expenses | CN¥5.09b |
| Earnings | CN¥1.55b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 84.98% |
| Net Profit Margin | 19.82% |
| Debt/Equity Ratio | 29.1% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
4.1%
Current Dividend Yield36%
Payout RatioDoes 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks| 3SBio dividend dates | |
|---|---|
| Ex Dividend Date | Jul 22 2024 |
| Dividend Pay Date | Aug 05 2024 |
| Days until Ex dividend | 87 days |
| Days until Dividend pay date | 101 days |
Does 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks